Journal ArticleDOI
Suicide Substrates, Mechanism-Based Enzyme Inactivators: Recent Developments
About:
This article is published in Annual Review of Biochemistry.The article was published on 1984-01-01. It has received 268 citations till now. The article focuses on the topics: Oxidoreductase & Enzyme inhibitor.read more
Citations
More filters
Book ChapterDOI
The Behavior and Significance of Slow-Binding Enzyme Inhibitors
Journal Article
Mechanisms of enhanced oral availability of CYP3A4 substrates by grapefruit constituents : Decreased enterocyte CYP3A4 concentration and mechanism-based inactivation by furanocoumarins
Phyllissa Schmiedlin-Ren,David J. Edwards,Michael E. Fitzsimmons,Kan He,Kenneth S. Lown,Patrick M. Woster,Atiqur Rahman,Kenneth E. Thummel,Jeannine M. Fisher,Paul F. Hollenberg,Paul B. Watkins +10 more
TL;DR: The effect of grapefruit juice on oral availability of CYP3A4 substrates can be largely accounted for by the presence of 6',7'-dihydroxybergamottin although other furanocoumarins probably also contribute.
Journal ArticleDOI
Development of a gut microbe-targeted nonlethal therapeutic to inhibit thrombosis potential
Adam B. Roberts,Adam B. Roberts,Xiaodong Gu,Xiaodong Gu,Jennifer A. Buffa,Jennifer A. Buffa,Alex G Hurd,Alex G Hurd,Alex G Hurd,Zeneng Wang,Zeneng Wang,Weifei Zhu,Weifei Zhu,Nilaksh Gupta,Nilaksh Gupta,Sarah M. Skye,Sarah M. Skye,David B. Cody,Bruce S. Levison,William T. Barrington,Matthew W Russell,Matthew W Russell,Jodie Michelle Reed,Ashraf Duzan,Ashraf Duzan,Jennifer M. Lang,Xiaoming Fu,Xiaoming Fu,Lin Li,Lin Li,Alex J Myers,Alex J Myers,Suguna Rachakonda,Suguna Rachakonda,Joseph A. DiDonato,Joseph A. DiDonato,J. Mark Brown,J. Mark Brown,Valentin Gogonea,Valentin Gogonea,Valentin Gogonea,Aldons J. Lusis,Jose C. Garcia-Garcia,Stanley L. Hazen,Stanley L. Hazen +44 more
TL;DR: These studies reveal that mechanism-based inhibition of gut microbial TMA and TMAO production reduces thrombosis potential, a critical adverse complication in heart disease, and offer a generalizable approach for the selective nonlethal targeting of Gut microbial enzymes linked to host disease limiting systemic exposure of the inhibitor in the host.
Journal ArticleDOI
Lipid biosynthesis as a target for antibacterial agents.
TL;DR: The site of action of isoniazid, used in the treatment of tuberculosis for 50 years, and the consumer antimicrobial agent triclosan were revealed recently to be the enoyl-ACP reductase of the type II FAS, which contrasts sharply with the type I FAS of eukaryotes.
Journal ArticleDOI
Prospects for new antibiotics: a molecule-centered perspective
TL;DR: This work brings a molecule-centered perspective to the questions of where will new scaffolds come from, when will chemogenetic approaches yield useful new antibiotics and what existing bacterial targets merit contemporary re-examination.